Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Interferon alpha 2b inhalation - Altum Pharmaceuticals/BetterLife Pharma

Drug Profile

Interferon alpha 2b inhalation - Altum Pharmaceuticals/BetterLife Pharma

Alternative Names: AntiCovir; AP 003 - Altum Pharmaceuticals; Interferon alpha 2b inhalation - BetterLife Pharma

Latest Information Update: 18 Nov 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Altum Pharmaceuticals; Unknown
  • Developer Altum Pharmaceuticals
  • Class Antineoplastics; Antivirals; Interferons
  • Mechanism of Action Interferon alpha-2 replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II COVID 2019 infections

Most Recent Events

  • 10 Nov 2020 BetterLife Pharma plans to file an IND application with US FDA in USA for COVID-2019 infections
  • 10 Nov 2020 BetterLife Pharma plans a clinical trisl for COVID-2019 infections in USA
  • 15 Oct 2020 BetterLife Pharma plans a clinical trial for COVID-2019 infections in Australia (Inhalation, Liquid) in late 2020
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top